Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Katja Gwin
Based on 1 article published since 2010
(Why 1 article?)
||||

Between 2010 and 2020, Katja Gwin wrote the following article about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Article The expression of FOXL2 in pancreatic, hepatobiliary, and renal tumors with ovarian-type stroma. 2014

Westerhoff, Maria / Tretiakova, Maria / Hart, John / Gwin, Katja / Liu, Xiuli / Zhou, Ming / Yeh, Matthew M / Antic, Tatjana. ·University of Washington Medical Center, Seattle, WA 98195. Electronic address: mwest2@uw.edu. · University of Washington Medical Center, Seattle, WA 98195. · University of Chicago Medical Center, Chicago, IL 60637. · Cleveland Clinic, Cleveland, OH 809835. · New York University, New York, NY 10012. ·Hum Pathol · Pubmed #24746205.

ABSTRACT: FOXL2, a gene encoding a member of the fork-head-winged-helix family of transcription factors, is one of the earliest expressed genes during female gonadal development. It is expressed in normal ovarian stroma and ovarian neoplasms with granulosa cell lineage. Nonovarian tumors such as pancreatic mucinous cystic neoplasms (PMCs), hepatobiliary cystadenomas (HBCs), and mixed epithelial and stromal tumor of the kidney (MEST) have ovarian-type stroma. Immunohistochemical staining with FOXL2, estrogen receptor, and progesterone receptor was performed on 21 PMCs, 13 HBCs, and 10 MESTs and assessed for nuclear immunohistochemical positivity in the tumor stroma. All cases of PMC and HBC demonstrated nuclear reactivity for FOXL2 in the subepithelial stromal cells. Ninety percent of MEST demonstrated nuclear FOXL2 positivity. Estrogen receptor nuclear positivity was demonstrated in 57% of PMC, 77% of HBC, and 80% of MEST. Progesterone receptor nuclear positivity was present in 67% of PMC, 100% of HBC, and 90% of MEST. Clinical information was available for 37 patients. Seventy-eight percent of the patients had a history of obesity, heavy alcohol use, or hormone-related therapy. The 2 male patients had histories significant for morbid obesity and chronic alcoholism. FOXL2 is expressed from the early stages of ovarian development and has been shown to be mandatory for normal ovarian function. We have shown that it is also expressed in the aberrant ovarian-type stroma characteristic of PMC, HBC, and MEST. Most of such patients, including the rare male patients, have risk factors for hormonal abnormalities such as obesity and hormonal replacement therapy.